BridgeBio Pharma, Inc. — Director's Dealing 2024

Dec 31, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2024-12-30

Reporting Person: Satvat Ali J. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-12-30	Common Stock	M	79702	$10.99	Acquired	79702	Direct
2024-12-30	Common Stock	M	39851	$16.68	Acquired	119553	Direct
2024-12-30	Common Stock	M	39851	$26.21	Acquired	159404	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-12-30	Stock Option (Right to Buy)	$10.99	M	79702	Disposed	2028-07-01	Common Stock (79702)	Direct
2024-12-30	Stock Option (Right to Buy)	$16.68	M	39851	Disposed	2029-06-12	Common Stock (39851)	Direct
2024-12-30	Stock Option (Right to Buy)	$26.21	M	39851	Disposed	2030-05-27	Common Stock (39851)	Direct

Footnotes

F1: The stock option was fully vested and exercisable on the date of issuance by the Issuer as of January 26, 2021.